Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1991 1
1992 3
1993 3
1994 4
1995 3
1996 9
1997 4
1998 7
1999 6
2000 9
2001 7
2002 15
2003 15
2004 5
2005 4
2006 9
2007 6
2008 4
2009 5
2010 2
2011 1
2013 1
2014 1
2015 2
2016 2
2019 2
2020 1
2021 1
2022 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, Lin H, Loewenstein A, Mohan S, Pearce IA, Sakamoto T, Schlottmann PG, Silverman D, Sun JK, Wells JA, Willis JR, Tadayoni R; YOSEMITE and RHINE Investigators. Wykoff CC, et al. Among authors: adamis ap. Lancet. 2022 Feb 19;399(10326):741-755. doi: 10.1016/S0140-6736(22)00018-6. Epub 2022 Jan 24. Lancet. 2022. PMID: 35085503 Clinical Trial.
Judah Folkman.
Adamis AP, Miller JW. Adamis AP, et al. Semin Ophthalmol. 2009 May-Jun;24(3):128-9. doi: 10.1080/08820530902800116. Semin Ophthalmol. 2009. PMID: 19437346 No abstract available.
Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
Holekamp NM, Campochiaro PA, Chang MA, Miller D, Pieramici D, Adamis AP, Brittain C, Evans E, Kaufman D, Maass KF, Patel S, Ranade S, Singh N, Barteselli G, Regillo C; all Archway Investigators. Holekamp NM, et al. Among authors: adamis ap. Ophthalmology. 2022 Mar;129(3):295-307. doi: 10.1016/j.ophtha.2021.09.016. Epub 2021 Sep 29. Ophthalmology. 2022. PMID: 34597713 Free article. Clinical Trial.
Conjunctival concretions.
Kowal VO, Adamis AP, Albert DM. Kowal VO, et al. Among authors: adamis ap. Am J Ophthalmol. 1992 Nov 15;114(5):640-1. doi: 10.1016/s0002-9394(14)74503-9. Am J Ophthalmol. 1992. PMID: 1443034 No abstract available.
Chlamydial ocular diseases.
An BB, Adamis AP. An BB, et al. Among authors: adamis ap. Int Ophthalmol Clin. 1998 Winter;38(1):221-30. doi: 10.1097/00004397-199803810-00017. Int Ophthalmol Clin. 1998. PMID: 9532483 Review. No abstract available.
Fuchs' endothelial dystrophy of the cornea.
Adamis AP, Filatov V, Tripathi BJ, Tripathi RC. Adamis AP, et al. Surv Ophthalmol. 1993 Sep-Oct;38(2):149-68. doi: 10.1016/0039-6257(93)90099-s. Surv Ophthalmol. 1993. PMID: 8235998 Review.
Molecular biology of choroidal neovascularization.
Lu M, Adamis AP. Lu M, et al. Among authors: adamis ap. Ophthalmol Clin North Am. 2006 Sep;19(3):323-34. doi: 10.1016/j.ohc.2006.05.001. Ophthalmol Clin North Am. 2006. PMID: 16935207 Review.
131 results